ARCT Arcturus Therapeutics Holdi...

Nasdaq arcturusrx.com


$ 11.28 $ -0.78 (-6.5 %)    

Friday, 24-Oct-2025 19:58:26 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 11.22
$ 12.00
$ 11.20 x 155
$ 11.30 x 25
$ 10.72 - $ 12.07
$ 8.04 - $ 24.17
3,862,057
na
304.67M
$ 2.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-arcturus-therapeutics-to-neutral-lowers-price-target-to-12

HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers...

 citigroup-downgrades-arcturus-therapeutics-to-neutral-lowers-price-target-to-12

Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers the price ...

 arcturus-investigational-inhaled-therapy-lacks-meaningful-lung-function-improvement-analyst-notes-mixed-picture

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but...

 btig-maintains-buy-on-arcturus-therapeutics-lowers-price-target-to-23

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $48 to...

 guggenheim-downgrades-arcturus-therapeutics-to-neutral

Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral.

 arcturus-announces-interim-results-from-ongoing-phase-2-clinical-trial-of-arct-032-investigational-inhaled-mrna-therapy-for-people-with-cystic-fibrosis

ARCT-032 generally safe and well toleratedMeaningful trends of clinical activity observed via high resolution CT scansAfter onl...

Core News & Articles

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

 cathie-woods-ark-bets-big-on-solana-treasury-play-makes-162m-investment-in-brera-holdings-as-stock-explodes-225

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and b...

 hc-wainwright--co-assumes-arcturus-therapeutics-at-buy-announces-price-target-of-60

HC Wainwright & Co. analyst Andrew S. Fein assumes Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces P...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION